DaVita

DVA

Market cap $15.1B

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.

DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $232.8, denoting a +1.45% move from the preceding trading day.

Greg Abel may have taken over as CEO, but he's not the only one making key investment decisions at Berkshire Hathaway. Berkshire's positions in DaVita and SiriusXM, reportedly selected by Ted Weschler, who manages a portion of the portfolio, have outperformed so far in 2026.

DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.

ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.

DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.